4D Molecular Therapeutics
5858 Horton St. Suite 455
Emeryville
California
94608
United States
Tel: 510-505-2680
Website: http://www.4dmoleculartherapeutics.com/
About 4D Molecular Therapeutics
4DMT is a gene therapy company with a transformative discovery platform --Therapeutic Vector Evolution --that enables our “disease first” approach to product discovery and development, thereby allowing us to customize our AAV vectors to target specific tissue types associated with the underlying disease.
At 4DMT we are creating and developing optimized “biopharmaceutical grade” AAV vectors that will allow us uniquely to unlock the full potential of gene therapy. Our customized and proprietary AAV vectors are each designed, according to a 4DMT Target Vector Profile, to deliver genes to specific cells and tissues in the body to eradicate both rare and large market diseases.
While AAV gene therapy pioneers are making great strides with the first wave of products, hurdles still exist with the use of conventional vectors. The most commonly used AAV capsids (e.g., AAV2, 5, 8 and 9) were identified either 1) as contaminants in lab stocks of adenovirus, or 2) through monkey tissue processing. Therefore, these conventional vectors are not targeted specifically to any tissue in the body. This can lead to inefficient and non-specific delivery, thus requiring extremely high doses and potentially resulting in toxicities (including inflammation), high manufacturing burdens and suboptimal efficacy. In addition, suboptimal routes of delivery can be required for delivery to the right tissues (e.g., subretinal delivery to the retina). Finally, pre-existing neutralizing antibodies in many patients can limit efficacy, clinical trial enrollment and market sizes. 4DMT Innovation empowers us to create new and improved next generation AAV capsids to allow targeted delivery of our products by the optimal clinical route of administration.
At 4DMT we use our robust discovery platform, termed “Therapeutic Vector Evolution,” to create customized and proprietary gene delivery vehicles (novel AAV vectors) to deliver genes to specific tissues and cells in the body by the optimal route of administration. We use the power of evolution to create and refine these optimized vectors through genetic diversification and then natural selection in vivo.
4D Purpose Statement: Boldly Innovating to Unlock the Full Potential of Gene Therapy for Countless Patients
GUIDING PRINCIPLES
- Dare to Cure - Patients are waiting. Create big dreams for patients and take calculated risks to achieve them
- Break Boundaries - Question the status quo and innovate beyond conventional approaches
- Beyond Yourself - It's about patients, their families, our team, our families. We strengthen each other.
- Prepare and Execute Relentlessly - Start with the end in mind, over-prepare and make contingency plans to your contingency plans
We invite all of you who share our passion and vision in creating the ultimate gene therapy products to cure genetic and rare diseases in children and adults. We seek the best people in the industry who identify with our mission and innovative results-driven approach. We offer an inspiring and collaborative environment that encourages individual contributions, recognizes performance in multiple ways, offers generous benefits and provides challenging opportunities for career development.
96 articles about 4D Molecular Therapeutics
-
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022
11/10/2022
4D Molecular Therapeutics, Inc. announced that enrollment has been completed in all 3 cohorts of the Phase 1 Dose Exploration stage of the Phase 1/2 clinical trial of intravitreal 4D-150 in patients with wet AMD.
-
4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results
11/9/2022
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today reported third quarter 2022 financial results.
-
4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022
11/3/2022
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that interim clinical data from the Phase 1/2 clinical trial of 4D-710 for cystic fibrosis lung disease were presented at the North American Cystic Fibrosis Conference (NACFC).
-
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022
10/26/2022
4D Molecular Therapeutics, Inc. announced that interim clinical data from the Phase 1/2 clinical trial of 4D-710 will be presented during a symposium at the upcoming North American Cystic Fibrosis Conference, being held November 3-5, 2022.
-
4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer
9/27/2022
4D Molecular Therapeutics, Inc. announced the appointment of Noriyuki (‘Nori’) Kasahara, MD, PhD to the Board of Directors.
-
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
9/20/2022
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that management will participate in the following upcoming investor conferences.
-
4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update
8/11/2022
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, reported second quarter 2022 financial results and provided a 4D-310 program update.
-
4D Molecular Therapeutics to Participate in Upcoming June Investor Conferences
6/2/2022
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that management will participate in the following upcoming investor conferences.
-
4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates
5/12/2022
4D Molecular Therapeutics, Inc. reported first quarter 2022 financial results and provided corporate updates.
-
4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference
5/5/2022
4D Molecular Therapeutics, Inc. announced that management will participate in the 2022 Bank of America Healthcare Conference on Tuesday, May 10th.
-
Evozyne inked a partnership with Takeda Pharmaceutical to develop next-generation gene therapies for up to four rare disease targets. Continue reading for that and more collaboration news from this week.
-
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710, an A101 AAV Vector-based, Aerosol-delivered Genetic Medicine for the Treatment of Cystic Fibrosis
4/4/2022
4D Molecular Therapeutics, Inc. announced that the first patient has been dosed in its Phase 1/2 clinical trial of 4D-710 in patients with cystic fibrosis.
-
4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights
3/28/2022
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced full year 2021 financial results and provided operational highlights.
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
-
BioSpace Movers & Shakers, Feb. 25
2/25/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
4D Molecular Therapeutics Announces Resignation of Professor David Schaffer, Ph.D. from the Company’s Board of Directors
2/22/2022
4D Molecular Therapeutics, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies announced that Professor David Schaffer, Ph.D. has resigned as a director of 4D Molecular Therapeutics.
-
4D Molecular Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
2/11/2022
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the 11th Annual SVB Leerink Global Healthcare Conference.
-
4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease at the 18th Annual WORLDSymposium
2/9/2022
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced updated interim clinical data from the ongoing Phase 1/2 clinical trial of 4D-310 in patients with Fabry disease at the 18th Annual WORLDSymposium.
-
4D Molecular Therapeutics to Present Updated Clinical Data with 4D-310 in Fabry Disease Patients in Platform Presentation at the 18th Annual WORLDSymposium
2/2/2022
4D Molecular Therapeutics announced updated interim clinical data from the on-going 4D-310 Phase 1/2 trial in patients with Fabry disease will be presented at the upcoming 18th Annual WORLDSymposium that will take place in San Diego, CA and virtually from February 7-11, 2022.
-
4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retinitis Pigmentosa
1/10/2022
4D Molecular Therapeutics (NASDAQ: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 4D-125 for treatment of patients with inherited retinal dystrophies due to defects in the RPGR gene, including X-linked Retinitis Pigmentosa (XLRP).